ANNA MALOVANNAYA to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications ANNA MALOVANNAYA has written about Xenograft Model Antitumor Assays.
Connection Strength
0.447
-
gpGrouper: A Peptide Grouping Algorithm for Gene-Centric Inference and Quantitation of Bottom-Up Proteomics Data. Mol Cell Proteomics. 2018 11; 17(11):2270-2283.
Score: 0.115
-
Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nat Commun. 2017 03 28; 8:14864.
Score: 0.105
-
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase. Blood Adv. 2025 Nov 11; 9(21):5598-5609.
Score: 0.048
-
Tobacco smoke exposure is a driver of altered oxidative stress response and immunity in head and neck cancer. J Transl Med. 2025 Apr 05; 23(1):403.
Score: 0.046
-
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Blood Cancer J. 2025 03 15; 15(1):40.
Score: 0.046
-
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood. 2025 02 06; 145(6):612-624.
Score: 0.045
-
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. Blood. 2024 05 16; 143(20):2059-2072.
Score: 0.043